NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $33.17 -0.79 (-2.33%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$33.67 +0.50 (+1.52%) As of 05/2/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Legend Biotech Stock (NASDAQ:LEGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Legend Biotech alerts:Sign Up Key Stats Today's Range$33.03▼$34.6750-Day Range$30.25▼$38.2452-Week Range$29.27▼$60.87Volume1.82 million shsAverage Volume1.23 million shsMarket Capitalization$6.09 billionP/E RatioN/ADividend YieldN/APrice Target$78.82Consensus RatingModerate Buy Company OverviewLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More… Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreLEGN MarketRank™: Legend Biotech scored higher than 54% of companies evaluated by MarketBeat, and ranked 472nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLegend Biotech has only been the subject of 4 research reports in the past 90 days.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.31) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -34.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -34.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.49% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Legend Biotech has recently decreased by 8.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.49% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Legend Biotech has recently decreased by 8.15%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.35 News SentimentLegend Biotech has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Legend Biotech this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address LEGN Stock News HeadlinesThe Play On Legend BiotechMay 3 at 4:51 AM | seekingalpha.comLegend Biotech to Host Investor Conference Call on First Quarter 2025 ResultsApril 29, 2025 | finance.yahoo.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 3, 2025 | Timothy Sykes (Ad)Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are BuyingApril 24, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Legend Biotech (LEGN)April 21, 2025 | markets.businessinsider.comBiotech stocks to own amid market volatility – Piper SandlerApril 11, 2025 | msn.comWhat Does the Market Think About Legend Biotech?April 3, 2025 | benzinga.comMarks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks FallApril 1, 2025 | markets.businessinsider.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $32.54 at the beginning of the year. Since then, LEGN stock has increased by 1.9% and is now trading at $33.17. View the best growth stocks for 2025 here. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) posted its earnings results on Tuesday, March, 11th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.46. The business's quarterly revenue was up 134.6% compared to the same quarter last year. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional investors include Massachusetts Financial Services Co. MA (1.24%), Matthews International Capital Management LLC (0.60%), Mirae Asset Global Investments Co. Ltd. (0.55%) and Bank of New York Mellon Corp (0.07%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF). Company Calendar Last Earnings3/11/2025Today5/03/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,070Year FoundedN/APrice Target and Rating Average Stock Price Target$78.82 High Stock Price Target$90.00 Low Stock Price Target$60.00 Potential Upside/Downside+137.6%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-66.92% Pretax MarginN/A Return on Equity-29.69% Return on Assets-19.45% Debt Debt-to-Equity Ratio0.27 Current Ratio4.98 Quick Ratio4.90 Sales & Book Value Annual Sales$627.24 million Price / Sales9.71 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book4.82Miscellaneous Outstanding Shares183,649,000Free Float182,597,000Market Cap$6.09 billion OptionableOptionable Beta0.21 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:LEGN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.